Breast Cancer

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: In postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer (BC), extending anastrozole treatment for an additional 5 years after initial 5-year treatment with anastrozole-containing hormone therapy improved disease-free survival (DFS) without any major adverse event occurrence.

Major finding: Continuation of anastrozole treatment for an additional 5 years significantly improved 5-year DFS (hazard ratio [HR] 0.62; P = .0010). The incidence of grade ≥3 adverse events was <1% in both groups, with no significant difference observed between both the groups.

Study details: Findings are from the phase 3, AERAS trial including 1593 postmenopausal women with HR+ early-stage invasive BC who were disease-free at 5 years after postoperative endocrine therapy and were randomly assigned to stop or continue receiving anastrozole for an additional 5 years.

Disclosures: This study was supported by Public Health Research Foundation, Japan. Several authors declared receiving honoraria or research funding or serving on speaker’s bureaus, in consulting roles, or in advisory roles for various sources.

Source: Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 Years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023 (Apr 20). Doi: 10.1200/JCO.22.00577

Key clinical point: In postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer (BC), extending anastrozole treatment for an additional 5 years after initial 5-year treatment with anastrozole-containing hormone therapy improved disease-free survival (DFS) without any major adverse event occurrence.

Major finding: Continuation of anastrozole treatment for an additional 5 years significantly improved 5-year DFS (hazard ratio [HR] 0.62; P = .0010). The incidence of grade ≥3 adverse events was <1% in both groups, with no significant difference observed between both the groups.

Study details: Findings are from the phase 3, AERAS trial including 1593 postmenopausal women with HR+ early-stage invasive BC who were disease-free at 5 years after postoperative endocrine therapy and were randomly assigned to stop or continue receiving anastrozole for an additional 5 years.

Disclosures: This study was supported by Public Health Research Foundation, Japan. Several authors declared receiving honoraria or research funding or serving on speaker’s bureaus, in consulting roles, or in advisory roles for various sources.

Source: Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 Years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023 (Apr 20). Doi: 10.1200/JCO.22.00577

Key clinical point: In postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer (BC), extending anastrozole treatment for an additional 5 years after initial 5-year treatment with anastrozole-containing hormone therapy improved disease-free survival (DFS) without any major adverse event occurrence.

Major finding: Continuation of anastrozole treatment for an additional 5 years significantly improved 5-year DFS (hazard ratio [HR] 0.62; P = .0010). The incidence of grade ≥3 adverse events was <1% in both groups, with no significant difference observed between both the groups.

Study details: Findings are from the phase 3, AERAS trial including 1593 postmenopausal women with HR+ early-stage invasive BC who were disease-free at 5 years after postoperative endocrine therapy and were randomly assigned to stop or continue receiving anastrozole for an additional 5 years.

Disclosures: This study was supported by Public Health Research Foundation, Japan. Several authors declared receiving honoraria or research funding or serving on speaker’s bureaus, in consulting roles, or in advisory roles for various sources.

Source: Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 Years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023 (Apr 20). Doi: 10.1200/JCO.22.00577

Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.

Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).

Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.

Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.

Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002

Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.

Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).

Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.

Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.

Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002

Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.

Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).

Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.

Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.

Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002

Key clinical point: Survival outcomes were worsened in women with triple-negative breast cancer (TNBC) who were prescribed monthly antibiotics after TNBC diagnosis.

Major finding: Each additional total and unique monthly antimicrobial prescription was associated with inferior breast cancer-specific survival (hazard ratio [HR] 1.05; 95% CI 1.01-1.08, and HR 1.18; 95% CI 1.13-1.24, respectively) and overall survival (HR 1.05; 95% CI 1.02-1.08, and HR 1.17; 95% CI 1.12-1.23, respectively), with the association sustaining through the third year after TNBC diagnosis.

Study details: This study analyzed the data of 772 women with stage I-III TNBC from the Oncoshare database (including integrated data of electronic medical records and California Cancer Registry) who were treated with or without standard cytotoxic chemotherapy, of which 654 women received antibiotics.

Disclosures: This study was supported by the Breast Cancer Research Foundation, New York, and other sources. The authors declared no conflicts of interest.

Source: Ransohoff JD et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053 (Apr 12). Doi: 10.1038/s41467-023-37636-0

Key clinical point: Survival outcomes were worsened in women with triple-negative breast cancer (TNBC) who were prescribed monthly antibiotics after TNBC diagnosis.

Major finding: Each additional total and unique monthly antimicrobial prescription was associated with inferior breast cancer-specific survival (hazard ratio [HR] 1.05; 95% CI 1.01-1.08, and HR 1.18; 95% CI 1.13-1.24, respectively) and overall survival (HR 1.05; 95% CI 1.02-1.08, and HR 1.17; 95% CI 1.12-1.23, respectively), with the association sustaining through the third year after TNBC diagnosis.

Study details: This study analyzed the data of 772 women with stage I-III TNBC from the Oncoshare database (including integrated data of electronic medical records and California Cancer Registry) who were treated with or without standard cytotoxic chemotherapy, of which 654 women received antibiotics.

Disclosures: This study was supported by the Breast Cancer Research Foundation, New York, and other sources. The authors declared no conflicts of interest.

Source: Ransohoff JD et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053 (Apr 12). Doi: 10.1038/s41467-023-37636-0

Key clinical point: Survival outcomes were worsened in women with triple-negative breast cancer (TNBC) who were prescribed monthly antibiotics after TNBC diagnosis.

Major finding: Each additional total and unique monthly antimicrobial prescription was associated with inferior breast cancer-specific survival (hazard ratio [HR] 1.05; 95% CI 1.01-1.08, and HR 1.18; 95% CI 1.13-1.24, respectively) and overall survival (HR 1.05; 95% CI 1.02-1.08, and HR 1.17; 95% CI 1.12-1.23, respectively), with the association sustaining through the third year after TNBC diagnosis.

Study details: This study analyzed the data of 772 women with stage I-III TNBC from the Oncoshare database (including integrated data of electronic medical records and California Cancer Registry) who were treated with or without standard cytotoxic chemotherapy, of which 654 women received antibiotics.

Disclosures: This study was supported by the Breast Cancer Research Foundation, New York, and other sources. The authors declared no conflicts of interest.

Source: Ransohoff JD et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053 (Apr 12). Doi: 10.1038/s41467-023-37636-0

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.

Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.

Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.

Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0

Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.

Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.

Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.

Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0

Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.

Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.

Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.

Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.

Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.

Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.

Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294

Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.

Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.

Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.

Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294

Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.

Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.

Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.

Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294